Fulgent Genetics

FLGT · NASDAQ

$20.33+$0.23 (+1.14%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $20.10

FLGT analyst rating

HoldConsensus of 1 analyst over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold1
Underperform0
Sell0

12-month price target · 3 analysts

Average $19.38 (−4.7% downside)

Low: $19.19
Now: $20.33
High: $19.95

Upgrades and downgrades

The latest rating actions, newest first

FLGT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Aug 4, 2026	Maintains	Neutral	$15.00 → $19.00	58%
Piper Sandler	May 5, 2026	Maintains	Neutral	$30.00 → $15.00	58%
Piper Sandler	Nov 11, 2025	Maintains	Neutral	$21.00 → $30.00	58%

The case for and against

Updated Oct 23, 2025

Bull case

Fulgent Genetics Inc. demonstrates a strong financial outlook supported by its proprietary gene probes, which offer significant cost and flexibility advantages compared to competitors relying on third-party kits. The company’s dual focus on laboratory services and therapeutic development positions it well within the growing market for genetic testing and cancer treatment, providing a diversified revenue stream. Additionally, Fulgent's majority revenue generation from the United States enhances its market stability and potential for continued growth.

Bear case

Fulgent Genetics faces a challenging landscape as it seeks to scale its oncology business, with potential deterioration in service quality during nationwide rollouts posing a significant risk. Additionally, competitive pressures from other core market players, who may enhance their offerings and customer service, threaten to negatively impact Fulgent's operating results and relative market strength. The company is also susceptible to unpredictable regulatory changes and volatile industry fundamentals, which could adversely affect expected revenues and earnings.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.